We are writing to you about the ProTECT III trial, a study to determine whether the medicine progesterone improves the outcomes of people with traumatic brain injury. We are sending this letter to notify you that the study has evaluated its primary hypothesis and published the results in the December 25, 2014 issue of the *New England Journal of Medicine*.

Disappointingly, the ProTECT results show that the treatment of acute traumatic brain injury with the hormone progesterone provides no significant benefit to patients when compared with placebo. The preclinical data on progesterone’s brain protective effects are compelling, but we were not able to show this in a large trial with traumatic brain injury.

As promised, we are contacting you to let you know the primary analysis is complete. Despite the study’s negative results, this research will still provide important data about traumatic brain injury.

More detailed information about the trial results, including a link to the primary research paper, is available at protectiii.com. You may also request that a copy of this publication be mailed to you by contacting our research team. Results will also be posted on clinicaltrials.gov.

Please call the study primary coordinator at ###-###-#### for information about treatment group assignments or any other questions you may have. We greatly appreciate your support of this research.